What is TGTX's P/E ratio?

TG Therapeutics Inc (TGTX) currently trades at a P/E ratio of 17.74.

TG Therapeutics Inc reports a Return on Equity (ROE) of 79.21%.

What is TGTX's dividend yield?

TG Therapeutics Inc offers a dividend yield of 0.00%.

What is TGTX's Quality Score?

Our AI rates TGTX's overall financial quality at 69 out of 100, based on profitability, growth, debt and earnings stability.

Is now a good time to buy TGTX?

Our AI Timing Score for TGTX is 70 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.

Which sector does TGTX belong to?

TG Therapeutics Inc is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange

TG Therapeutics Inc (TGTX) Stock Price

Stock Check Daily update data at 8:30 AM
(Price: 2026-07-31 | FS: 2026-03-31)

TGTX AI Analysis Summary

Our AI summary for TGTX: TG Therapeutics Inc (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 17.74, ROE of 79.21%, a dividend yield of 0.00%. Its financial Quality Score stands at 69/100 — mid-range fundamentals relative to the market. The AI Timing Score is 70/100 — multiple technical signals currently support price momentum. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.

TGTX

TG Therapeutics Inc

US:NASDAQ STOCK Healthcare >> Biotechnology News 85

USD 52.03

-1.50 (-2.80%) Day Change

Watchlist Portfolio Compare Chart

17.74

P/E

1.28

D/E

79.2%

ROE

30.2%

ROA

0.00%

Div Yield

0.03

PEG

TG THERAPEUTICS INC
TYPE: STOCK
MARKET: NASDAQ

Compare Watchlist Myport

USD 52.03 Price -1.50 (-2.80%) Day Change	NEWS SCORE: 85

TGTX, the overall quality is ok ( Quality = 69) and the timing to buy is ...(Sign In to See)...

Loading chart...

69 QUALITY

Signal: NEUTRAL

Signal Description: Company financial health is OK

Reason: Historical ROE is relatively low
ROA is too relatively low compare to ROE
Current growth of ROA was below our criteria.
Historical net profit margin is relatively low.

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Momentum indicators aligned on the daily timeframe

Unlock timing signals and detailed reasons

In details, quality factors are ok , financial health is not good , and ability to make profit is ok , ...

Quality Factors

61%

In Recommendations?	In "Invest - GROWTH" Section
Select Rate	0.00 From 30 days period
Watch Rate	0.23 From 30 days period
News Score	85
Magic Formula Rank by ROA	450
Magic Formula Rank by ROE	450
Magic Formula Rank by ROIC	659
Price	52.03
PBV / Sector	14.05 / 5.20
Earning Per Share	2.93

PE / Sector	17.74 / 19.97
PEG or PE/Growth / Sector	0.03 / 1.22 GREAT
Average 1M Daily Value	112.04 M GREAT
Average 1W Daily Value	131.17 M GREAT

Timing Factors

42%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Financial Health

43%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

Ability to Make Profit

66%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	65.95 / 98.71 GREAT
NPM Average (%) / Sector	-1,577.06 / -1,721.76
NPM Change Average (%) / Sector	210.70 / 5,211.62 GREAT
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	30.21 / 27.02 GREAT
ROA Average (%) / Sector	-7.09 / -368.17
ROA Change Average (%) / Sector	203.21 / 5,404.12 GREAT
ROE (%) / Sector	79.21 / 3.47 GREAT
ROE Average (%) / Sector	-43.08 / 6.51
ROE Change Average (%) / Sector	125.54 / 2,128.13 GREAT
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

Return to Investors

Dividend (%) / Sector	N/A / 0.04
Dividend Average (%) / Sector	N/A / 17.04
Dividend Change Average (%) / Sector	N/A / -1.75

Registration Details

Analyze Date	2026-08-01 08:00:34
Symbol	TGTX
Name	TG THERAPEUTICS INC
Sector	Healthcare >> Biotechnology
Market	NASDAQ
Listed Shares	153.08 M
Par Value	N/A
Calculated From	Quarter
Sign	N/A
Market Cap (M.USD) / Sector Average	8,194.56 / 9,903.94

News, Concensus, ...

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: 3020 Carrington Mill Blvd., Morrisville, NC, United States, 27560

Phone: 212 554 4484

Website: https://www.tgtherapeutics.com

Employees: 399

Sector: Healthcare >> Biotechnology

Description: TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. The company provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Ublituximab IV, glycoengineered anti-CD20 mAb for the treatment of relapsing MS; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Jiangsu Hengrui Medicine Co. The company was incorporated in 1993 and is based in Morrisville, North Carolina.